Last reviewed · How we verify

NCT03152240: TAPAC

Coronary Anatomy Study and Times Since the Onset of Acute Myocardial Infarction Symptoms in Women Until the Opening of the Artery (TAPAC Study)

Completed Last updated 27 February 2019
What this trial tests

trial testing Non intervention in Myocardial Infarction in 800 participants. Completed in 26 February 2019.

Timeline
1 November 2017
Primary endpoint
26 February 2019
26 February 2019

Quick facts

Lead sponsorHospital Universitari Vall d'Hebron Research Institute
StatusCompleted
Study typeOBSERVATIONAL
Enrollment800
Start date1 November 2017
Primary completion26 February 2019
Estimated completion26 February 2019
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Hospital Universitari Vall d'Hebron Research Institute

Who can join

18 and older, any sex, with Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

TAPAC study is an an investigator-driven, observational, prospective,cohort aimed at evaluating differences between men and women in patients undergoing primary angioplasty : hospital medical care, successful markers myocardial reperfusion and the anatomical substrate by describing the underlying coronary anatomy will be compared.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Non intervention

Trials testing the same drug.

Other recruiting trials for Myocardial Infarction

Currently open trials in the same condition.

Other Hospital Universitari Vall d'Hebron Research Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03152240.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing